aristolochic acid i has been researched along with sirolimus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Chen, G; Chen, H; Liu, F; Liu, H; Peng, Y; Sun, L; Wang, C | 1 |
| Chen, B; Lin, F; Liu, Y; Ren, Y; Song, Y; Tang, L; Xu, X; Yang, X; Zhang, X | 1 |
3 other study(ies) available for aristolochic acid i and sirolimus
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts.
Topics: Animals; Aristolochic Acids; Cell Line; Cell Proliferation; Extracellular Matrix; Fibroblasts; Fibrosis; Immunosuppressive Agents; Intestines; Kidney Diseases; Macrophages; Mice; Mice, Inbred C57BL; Mutagens; Myofibroblasts; NIH 3T3 Cells; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transforming Growth Factor beta1 | 2012 |
Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin‑mediated autophagy.
Topics: Animals; Apoptosis; Aristolochic Acids; Autophagy; Cell Line; Disease Models, Animal; Humans; Kidney Diseases; Male; Mice, Inbred C57BL; Protective Agents; Sirolimus; TOR Serine-Threonine Kinases | 2021 |